Results 31 to 40 of about 35,844 (219)

The new way of Dabigatran reversal – Idarucizumab

Journal of Education, Health and Sport, 2019
Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański, Krystian Ciechański, Magda Ciechańska, Jarosław Szponar   +3 more
doaj   +3 more sources

NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]

, 2016
Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne, Hicks, Tim, Stewart, Fiona   +2 more
core   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2020
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +1 more source

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +1 more source

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2022
Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu, Chenyue Qian, Cunjing Su, Hong Tao, Jiaojiao Mao, Zhening Guo, Xinyi Zhu, Jie Pan   +7 more
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Рациональная фармакотерапия в кардиологии, 2016
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj   +1 more source

Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial [PDF]

, 2012
Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and requires careful safety management. The aim of this study is to investigate whether a best practice model that applies major elements of case ...
A Siebenhofer, A Siebenhofer, A Siebenhofer, Andrea Berghold, Andrea Siebenhofer, AS Go, C Guethlin, C Heneghan, C Heneghan, CD Furberg, DE Morisky, EH Wagner, Ferdinand M Gerlach, FR Rosendaal, I Schafer, Ina Roehl, J Ansell, J Gensichen, J Gensichen, J Hirsh, Juliana J Petersen, K Goetz, K Saal, Karola Mergenthal, Lisa R Ulrich, M Connock, M Man-Son-Hing, M Nabauer, M Ufer, M von Korff, MJ Campbell, MJ Campbell, MR Patel, N Dagres, N Oake, PT Sawicki, R Bucheler, S Schulman, Sandra Rauck, Sebastian Harder, SJ Connolly, SL Norris, T Rosemann, TD Christensen, TD Hua, The EuroQol Group   +45 more
core   +2 more sources

Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran

Clinical and Applied Thrombosis/Hemostasis, 2020
The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD, Leszek Drabik MD, PhD, Magdalena Kaźnica-Wiatr MD, PhD, Lidia Tomkiewicz-Pająk MD, PhD, Piotr Podolec MD, PhD, Maria Olszowska MD, PhD   +5 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source